Recombinant Human Glypican 3 Protein 2119-GP-050 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemRecombinant Human Glypican 3 Protein
CompanyR&D Systems, a Bio-Techne Brand
Price $491.00Supplier Page View Company Product Page
Catalog Number2119-GP-050
SpeciesHuman
Molecule NameGlypican 3
Size50 ug
NCBI Full Gene Nameglypican 3
NCBI Gene AliasesSGBS1, DGSX, GTR2-2, SGB, OCI-5, SDYS, MXR7, SGBS
FormatLyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein
Purity>97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
Molecular WeightObserved: 60-100 kDa, non-reducing conditions
Theoretical: 61.6 kDa
ApplicationsBinding Activity
Conjugate/TagUnconjugated
Source/Expression SystemNS0-derived Recombinant Human Glypican 3 Protein
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

(1) BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activityPloS oneJanuary 1, 2022Hickman TL, Choi E, Whiteman KR, Muralidharan S, Pai T, Johnson T, Parikh A, Friedman T, Gilbert M, Shen B, et al.BOXR1030 T cells were activated with immobilized recombinant GPC3 protein (0.3 ug/mL) (R&D Systems, Cat# 2119-GP-050) over a 6-day time course. Following activation, samples were washed once with PBS and lysed in RIPA buffer

(3) Usefulness of plasma full-length glypican-3 as a predictive marker of hepatocellular carcinoma recurrence after radial surgeryOncology lettersApril 1, 2020Miura M, Fujinami N, Shimizu Y, Mizuno S, Saito K, Suzuki T, Konishi M, Takahashi S, Gotohda N, Suto K, et al.

(5) Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survivalClinical cancer research : an official journal of the American Association for Cancer ResearchJuly 1, 2012Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, et al.

(6) Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinomaClinical cancer research : an official journal of the American Association for Cancer ResearchMay 1, 2006Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, et al.

Recombinant Human Glypican 3 Protein